TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.67
52-Week Change 3-45.18%
S&P500 52-Week Change 318.19%
52 Week High 36.0900
52 Week Low 31.8200
50-Day Moving Average 32.7718
200-Day Moving Average 32.8976

Share Statistics

Avg Vol (3 month) 33.51M
Avg Vol (10 day) 32.56M
Shares Outstanding 5271.18M
Float 237.14M
% Held by Insiders 117.76%
% Held by Institutions 178.61%
Shares Short (Nov 15, 2019) 482.18M
Short Ratio (Nov 15, 2019) 419.41
Short % of Float (Nov 15, 2019) 446.75%
Short % of Shares Outstanding (Nov 15, 2019) 430.31%
Shares Short (prior month Oct 15, 2019) 487.51M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2100/1
Last Split Date 3Oct 3, 2011

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-373.21%

Management Effectiveness

Return on Assets (ttm)-37.22%
Return on Equity (ttm)-294.02%

Income Statement

Revenue (ttm)38.83M
Revenue Per Share (ttm)0.16
Quarterly Revenue Growth (yoy)582.90%
Gross Profit (ttm)13.36M
EBITDA -144.46M
Net Income Avi to Common (ttm)-166.1M
Diluted EPS (ttm)-0.6910
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)155.33M
Total Cash Per Share (mrq)0.57
Total Debt (mrq)205.1M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)2.85
Book Value Per Share (mrq)-0.09

Cash Flow Statement

Operating Cash Flow (ttm)-143.05M
Levered Free Cash Flow (ttm)-69.5M